

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 8, 2002, 22:23:50 ; Search time 37.6 Seconds  
(without alignments)  
892.426 Million cell updates/sec

Title: US-09-635-521A-2  
Perfect score: 2334  
Sequence: 1 MASPIRPGSDCSQIIDHSV.....NSGAKPANSAAENGQHEHV 453

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues  
Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

1: /SIDB2/gcgdata/geneseq/AA1980.DAT.\*  
2: /SIDB2/gcgdata/geneseq/AA1981.DAT.\*  
3: /SIDB2/gcgdata/geneseq/AA1982.DAT.\*  
4: /SIDB2/gcgdata/geneseq/AA1983.DAT.\*  
5: /SIDB2/gcgdata/geneseq/AA1984.DAT.\*  
6: /SIDB2/gcgdata/geneseq/AA1985.DAT.\*  
7: /SIDB2/gcgdata/geneseq/AA1986.DAT.\*  
8: /SIDB2/gcgdata/geneseq/AA1987.DAT.\*  
9: /SIDB2/gcgdata/geneseq/AA1988.DAT.\*  
10: /SIDB2/gcgdata/geneseq/AA1989.DAT.\*  
11: /SIDB2/gcgdata/geneseq/AA1990.DAT.\*  
12: /SIDB2/gcgdata/geneseq/AA1991.DAT.\*  
13: /SIDB2/gcgdata/geneseq/AA1992.DAT.\*  
14: /SIDB2/gcgdata/geneseq/AA1993.DAT.\*  
15: /SIDB2/gcgdata/geneseq/AA1994.DAT.\*  
16: /SIDB2/gcgdata/geneseq/AA1995.DAT.\*  
17: /SIDB2/gcgdata/geneseq/AA1996.DAT.\*  
18: /SIDB2/gcgdata/geneseq/AA1997.DAT.\*  
19: /SIDB2/gcgdata/geneseq/AA1998.DAT.\*  
20: /SIDB2/gcgdata/geneseq/AA1999.DAT.\*  
21: /SIDB2/gcgdata/geneseq/AA2000.DAT.\*  
22: /SIDB2/gcgdata/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	852	36.5	167	21	Gene 28 human secr
2	852	36.5	167	21	Human secreted pro
3	852	36.5	167	22	Gene 13 human secr
4	852	36.5	167	22	Human secreted pro
5	470.5	20.2	418	17	Human neurotensin
6	404	17.3	410	19	Human type 2 neuro
7	404	17.3	410	21	Human NTRIP protel
8	403.5	17.3	353	15	G-protein coupled
9	403.5	17.3	353	17	G-protein coupled
10	370.5	15.9	319	19	Human neurotensin
11	364	15.6	395	22	Amino acid sequenc

12	363	15.6	405	21	AAV44641	Mouse growth hormo
13	363	15.6	405	22	AAE99186	Marine FM-3. Mus
14	363	15.6	412	22	AAE67803	Amino acid sequenc
15	363	15.6	415	21	AAV71296	Human orphan G pro
16	363	15.6	415	21	AAE02830	Human G protein co
17	363	15.6	415	22	AAE63353	Amino acid sequenc
18	363	15.6	415	22	AAE64297	Human GTP-binding
19	363	15.6	415	22	AAE03629	Human G-protein co
20	363	15.6	415	22	AAE67802	Amino acid sequenc
21	362	15.5	415	22	AAE03634	Rat G-protein coup
22	362	15.5	415	21	AAV52992	Human neurotensin-
23	362	15.5	415	22	AAE63366	Amino acid sequenc
24	361	15.5	415	22	AAE67805	Amino acid sequenc
25	361	15.5	415	22	AAE67804	Amino acid sequenc
26	355.5	15.2	412	21	AAV51145	Long form of motil
27	355.5	15.2	412	22	AAE62652	Amino acid sequenc
28	355.5	15.2	412	22	AAE68478	Human G protein co
29	349.5	15.0	412	21	AAE02854	Human G protein-co
30	346.5	14.8	403	21	AAV90638	Human growth hormo
31	346.5	14.8	403	21	AAV44642	Human FM-3. Homo
32	346.5	14.8	403	22	AAE99185	Human G-protein co
33	346.5	14.8	426	22	AAE03628	Rat FM-3. Ratius
34	345.5	14.8	412	22	AAE99199	Rat G-protein coup
35	345.5	14.8	413	22	AAE03635	Rat G-protein coup
36	345.5	14.8	439	22	AAE03636	Human mutant G pro
37	344.5	14.8	403	21	AAV90673	The puffer fish mo
38	327.5	14.0	363	21	AAV54147	Amino acid sequenc
39	327.5	14.0	363	22	AAE68479	Amino acid sequenc
40	324.5	13.9	400	22	AAE68477	A canine growth ho
41	320	13.7	349	21	AAV69293	Pig growth hormone
42	310	13.3	353	18	AAV19608	Swine growth hormo
43	310	13.3	353	18	AAV19215	A mouse growth hor
44	310	13.3	364	21	AAV54565	Rat growth hormone
45	308	13.2	364	22	AAE97577	

#### ALIGNMENTS

RESULT 1  
ID AAB63203 standard; Protein: 167 AA.  
XX AC AAB63203;  
XX DT 26-MAR-2001 (first entry)  
XX DE  
XX DE Gene 28 human secreted protein homologous amino acid sequence #129.  
KW Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;  
KW antithrombotic; antiproliferative; cytosolic; cardiant; vasotrophic;  
KW cerebroprotective; nootropic; neuroprotective; antibacterial; virulence;  
KW fungicide; ophthalmological; gene therapy; autoimmune disease; neoplasm;  
KW rheumatoid arthritis; hyperproliferative disorder; cardiac arrest;  
KW cardiovascular disorder; cerebrovascular disorder; cerebral ischemia;  
KW angiogenesis; nervous system disorder; Alzheimer's disease; infection;  
KW ocular disorder; corneal infection; wound healing; skin aging;  
KW food additive; preservative.  
XX OS Homo sapiens.  
XX PN W0200061629-A1.  
XX PD 19-OCT-2000.  
XX PF 06-APR-2000; 2000WO-US09071.  
XX PR 09-APR-1999; 99US-0128694.  
XX PR 20-JAN-2000; 2000US-0176931.  
XX PA (HUMA-) HUMAN GENOME SCI INC.  
XX PA (ROSE/) ROSEN C A.

PI Ruben SM, Komatsoulis G;  
 XX WPI: 2000-647420/62.  
 DR Isolated nucleic acid molecule encoding a human secreted protein is  
 XX used in preventing, treating or ameliorating a medical condition -  
 PT  
 XX Disclosure: Page 506-507; 533pp; English.  
 PS  
 XX AAF22373 to AAF22421 encode the human secreted proteins given in AAB63134  
 CC to AAB63182. AAB63183 to AAB63231 represent more human secreted proteins  
 CC and polypeptides homologous to them. Human secreted proteins have  
 CC activities based on the tissues and cells the genes are expressed in.  
 CC Examples of activities include: immunosuppressive; antiarthritic;  
 CC antineumatic; antiproliferative; cytostatic; cardiant; vasotropic;  
 CC cerebroprotective; neurotropic; neuroprotective; antibacterial; vitruide;  
 CC fungicide; and ophthalmological. The polynucleotides and proteins can be  
 CC used to prevent, treat or ameliorate a medical condition in e.g. humans,  
 CC mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are  
 CC also used in diagnosing a pathological condition or susceptibility to a  
 CC pathological condition. Disorders which are diagnosed or treated include  
 CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative  
 CC disorders e.g. neoplasms of the breast or liver, cardiovascular  
 CC disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral  
 CC ischaemia, angioneurosis, nervous system disorders e.g. Alzheimer's  
 CC disease, infections caused by bacteria, viruses and fungi and ocular  
 CC disorders e.g. corneal infection. The polypeptides can also be used to  
 CC aid wound healing and epithelial cell proliferation, to prevent skin  
 CC aging due to sunburn, to maintain organs before transplantation, for  
 CC supporting cell culture of primary tissues, to regenerate tissues and in  
 CC chemotaxis. The polypeptides can also be used as a food additive or  
 CC preservative to increase or decrease storage capabilities. AAF22364 to  
 CC AAF22372 and AAB63133 represent sequences used in the exemplification of  
 CC the present invention.  
 XX  
 SO Sequence 167 AA:  
 Query Match 36.5%; Score 852; DB 21; Length 167;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-80;  
 Matches 167; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 287 L I V V T L A V C W M P N Q I R I M A A K P K H D W T R S Y R A V M I L P S E T F F Y L S S V I N P L I Y T V 346  
 DB 1 I I V V L A V C W M P N Q I R I M A A K P K H D W T R S Y R A V M I L P S E T F F Y L S S V I N P L I Y T V 60  
 QY 347 S S O O F R R V F V O V L C C R L S L O H A N H E K R L R V H A S T D S A F V Q R L L P A S R R O S S A R T E 406  
 DB 61 S S G Q F I R V I V G L C C R L S I G H A N H E K R I R V H A S T D S A F V Q R L L P A S R R O S S A R T E 120  
 QY 407 K I F L S T F Q S E A P Q S K S Q S L S L E S L E P N S G A K P A N S A A E N G F Q E H E V 453  
 DB 121 K I F I S T F G S A E P Q S K S Q S L S L E P N S G A K P A N S A A E N G F G E H E V 167  
 RESULT 2  
 AAB63204  
 ID AAB63204 standard; Protein: 167 AA.  
 XX AAB63204:  
 AC  
 XX 26-MAR-2001 (first entry)  
 DT  
 XX Human secreted protein sequence encoded by gene 28 SEQ ID NO:130.  
 DE  
 XX Human: secreted protein; diagnosis; immunosuppressive; antiarthritic;  
 KW antirhumatic; antiproliferative; cytostatic; cardiant; vasotropic;  
 KW cerebroprotective; neurotropic; neuroprotective; antibacterial; vitruide;  
 KW fungicide; ophthalmological; gene therapy; autoimmune disease; neoplasm;  
 KW rheumatoid arthritis; hyperproliferative disorder; cardiac arrest;  
 KW cardiovascular disorder; cerebrovascular disorder; cerebral ischaemia;  
 KW angioneurosis; nervous system disorder; Alzheimer's disease; infection;  
 KW ocular disorder; corneal infection; wound healing; skin aging;

KW food additive; preservative.  
 XX  
 OS Homo sapiens.  
 XX W0200061629-A1.  
 XX  
 XX 19-OCR-2000.  
 PD  
 XX  
 XX 06-APR-2000; 2000WO-US09071.  
 PF  
 XX 09-APR-1999; 99US-0128694.  
 PR 20-JAN-2000; 2000US-0176931.  
 XX  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA (ROSE/) ROSEN C A.  
 PI Ruben SM, Komatsoulis G;  
 XX WPI: 2000-647420/62.  
 DR Isolated nucleic acid molecule encoding a human secreted protein is  
 XX used in preventing, treating or ameliorating a medical condition -  
 PT  
 XX Disclosure: Page 507-508; 533pp; English.  
 PS  
 XX AAF22373 to AAF22421 encode the human secreted proteins given in AAB63134  
 CC to AAB63182. AAB63183 to AAB63231 represent more human secreted proteins  
 CC and polypeptides homologous to them. Human secreted proteins have  
 CC activities based on the tissues and cells the genes are expressed in.  
 CC Examples of activities include: immunosuppressive; antiarthritic;  
 CC antineumatic; antiproliferative; cytostatic; cardiant; vasotropic;  
 CC cerebroprotective; neurotropic; neuroprotective; antibacterial; vitruide;  
 CC fungicide; and ophthalmological. The polynucleotides and proteins can be  
 CC used to prevent, treat or ameliorate a medical condition in e.g. humans,  
 CC mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are  
 CC also used in diagnosing a pathological condition or susceptibility to a  
 CC pathological condition. Disorders which are diagnosed or treated include  
 CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative  
 CC disorders e.g. neoplasms of the breast or liver, cardiovascular  
 CC disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral  
 CC ischaemia, angioneurosis, nervous system disorders e.g. Alzheimer's  
 CC disease, infections caused by bacteria, viruses and fungi and ocular  
 CC disorders e.g. corneal infection. The polypeptides can also be used to  
 CC aid wound healing and epithelial cell proliferation, to prevent skin  
 CC aging due to sunburn, to maintain organs before transplantation, for  
 CC supporting cell culture of primary tissues, to regenerate tissues and in  
 CC chemotaxis. The polypeptides can also be used as a food additive or  
 CC preservative to increase or decrease storage capabilities. AAF22364 to  
 CC AAF22372 and AAB63133 represent sequences used in the exemplification of  
 CC the present invention.  
 XX  
 SO Sequence 167 AA:  
 Query Match 36.5%; Score 852; DB 21; Length 167;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-80;  
 Matches 167; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 287 L I V V T L A V C W M P N Q I R I M A A K P K H D W T R S Y R A V M I L P S E T F F Y L S S V I N P L I Y T V 346  
 DB 1 I I V V L A V C W M P N Q I R I M A A K P K H D W T R S Y R A V M I L P S E T F F Y L S S V I N P L I Y T V 60  
 QY 347 S S O O F R R V F V O V L C C R L S L O H A N H E K R L R V H A S T D S A F V Q R L L P A S R R O S S A R T E 406  
 DB 61 S S G Q F I R V I V G L C C R L S I G H A N H E K R I R V H A S T D S A F V Q R L L P A S R R O S S A R T E 120  
 QY 407 K I F L S T F Q S E A P Q S K S Q S L S L E S L E P N S G A K P A N S A A E N G F Q E H E V 453  
 DB 121 K I F I S T F G S A E P Q S K S Q S L S L E P N S G A K P A N S A A E N G F G E H E V 167  
 RESULT 3  
 AAB75565

ID AAB75565 standard; Protein: 167 AA.  
 XX AAB75565;  
 AC  
 XX 06-APR-2001 (first entry)  
 DT  
 XX Gene 13 human secreted protein homologous amino acid sequence #119.  
 DE  
 XX Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;  
 KW antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;  
 KW neurotropic; neuroprotective; antibacterial; virucide; fungicide;  
 KW ophthalmological; vulnary; autoimmune disease; cardiovascular disorder;  
 KW hyperproliferative disorders; cerebrovascular disorder; wound healing;  
 KW nervous system disorder; ocular disorder; skin aging; chemotaxis;  
 KW food additive.  
 KW  
 XX Homo sapiens.  
 OS  
 XX MO200077026-A1.  
 PN  
 XX 21-DEC-2000.  
 PF  
 XX 01-JUN-2000; 2000MO-US14973.  
 PR  
 XX 11-JUN-1999; 99US-0138630.  
 PA  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA (ROSE/) ROSEN C A.  
 XX  
 PI Rosen CA, Ruben SM, Komatsoulis GA;  
 DR WPI: 2001-071258/08.  
 XX  
 PT Nucleic acid molecules encoding human secreted proteins, used in  
 PT preventing, treating or ameliorating a disorder, e.g. Alzheimer's and  
 PT Parkinson's diseases and cancers -  
 XX  
 PS Disclosure: Page 39; 542pp; English.  
 XX  
 CC Human secreted proteins AAB75506 - AAB75554 are encoded by polynucleotide  
 CC sequences AAF64176 - AAF64224. The specification includes amino acid  
 CC sequences AAB75555 - AAB75606 which represent fragments of the human  
 CC secreted proteins, and protein sequences with which they share homology.  
 CC The proteins and polynucleotides, their agonists and antagonists have  
 CC activities dependent on the tissues and cells in which they are  
 CC expressed, examples of these activities include, immunosuppressive;  
 CC antirheumatic; antirheumatic; antiproliferative; cytostatic; cardiant;  
 CC vasotropic; cerebroprotective; neurotropic; neuroprotective; antibacterial;  
 CC virucide; fungicide; ophthalmological; and vulnary. The proteins,  
 CC polynucleotides, agonists and antagonists can be used to treat or detect  
 CC or diagnose various diseases and disorders including, autoimmune  
 CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders  
 CC e.g. neoplasms of the breast or liver, cardiovascular disorders  
 CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,  
 CC angiogenesis, nervous system disorders e.g. Alzheimer's disease,  
 CC infections caused by bacteria, viruses and fungi and ocular disorders  
 CC e.g. corneal infection. The polypeptides can also be used to aid wound  
 CC healing and epithelial cell proliferation, to prevent skin aging due to  
 CC sunburn, to maintain organs before transplantation, for supporting cell  
 CC culture of primary tissues, to regenerate tissues and in chemotaxis. The  
 CC polypeptides can also be used as a food additive or preservative to  
 CC increase or decrease storage capabilities. Included in the invention are  
 CC polynucleotide sequences AAF64167 - AAF64175 and peptide AAB75505 which  
 CC are used in the isolation, identification and characterisation of the  
 CC proteins of the invention.  
 CC  
 XX Sequence 167 AA:  
 SO

Query Match 36.5%; Score 852; DB 22; Length 167;

Best Local Similarity 100.0%; Pred. No. 1.2e-80;

Matches 167; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 287 LIYVTLAVGCMQIRIRMAAKPKHDWTRSPRAYMILLPESEFPYLSYINPLLYTV 346  
 DB 1 LIYVTLAVGCMQIRIRMAAKPKHDWTRSPRAYMILLPESEFPYLSYINPLLYTV 60  
 QY 347 SSQOFRFRVFOVLCRSLSDHANHEKRLRVHAHSTDSARFVORPLFASRRQSSARTE 406  
 DB 61 ssqgfrfrvfgvlgcrlslsdhanhekrllrvhahstdsarfvgprllfssrrqsarrrte 120  
 QY 407 KIFLSTFQSEAPQSKSGLSELPNSGAKPANSANGFOHEHY 453  
 DB 121 kiflftqseapqsksgslslelpnsgakpansaangfohehev 167  
 RESULT 4  
 ID AAB75566 standard; Protein: 167 AA.  
 XX AAB75566;  
 AC  
 XX 06-APR-2001 (first entry)  
 DT  
 XX Human secreted protein sequence encoded by gene 13 SEQ ID NO:120.  
 DE  
 XX Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;  
 KW antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;  
 KW neurotropic; neuroprotective; antibacterial; virucide; fungicide;  
 KW ophthalmological; vulnary; autoimmune disease; cardiovascular disorder;  
 KW hyperproliferative disorders; cerebrovascular disorder; wound healing;  
 KW nervous system disorder; ocular disorder; skin aging; chemotaxis;  
 KW food additive.  
 KW  
 XX Homo sapiens.  
 OS  
 XX MO200077026-A1.  
 PN  
 XX 21-DEC-2000.  
 PF  
 XX 01-JUN-2000; 2000MO-US14973.  
 PR  
 XX 11-JUN-1999; 99US-0138630.  
 PA  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA (ROSE/) ROSEN C A.  
 XX  
 PI Rosen CA, Ruben SM, Komatsoulis GA;  
 DR WPI: 2001-071258/08.  
 DR N-PSDB; AAF64188.  
 XX  
 PT Nucleic acid molecules encoding human secreted proteins, used in  
 PT preventing, treating or ameliorating a disorder, e.g. Alzheimer's and  
 PT Parkinson's diseases and cancers -  
 XX  
 PS Disclosure: Page 39; 542pp; English.  
 XX  
 CC Human secreted proteins AAB75506 - AAB75554 are encoded by polynucleotide  
 CC sequences AAF64176 - AAF64224. The specification includes amino acid  
 CC sequences AAB75555 - AAB75606 which represent fragments of the human  
 CC secreted proteins, and protein sequences with which they share homology.  
 CC The proteins and polynucleotides, their agonists and antagonists have  
 CC activities dependent on the tissues and cells in which they are  
 CC expressed, examples of these activities include, immunosuppressive;  
 CC antirheumatic; antirheumatic; antiproliferative; cytostatic; cardiant;  
 CC vasotropic; cerebroprotective; neurotropic; neuroprotective; antibacterial;  
 CC virucide; fungicide; ophthalmological; and vulnary. The proteins,  
 CC polynucleotides, agonists and antagonists can be used to treat or detect  
 CC or diagnose various diseases and disorders including, autoimmune  
 CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders  
 CC e.g. neoplasms of the breast or liver, cardiovascular disorders  
 CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,  
 CC angiogenesis, nervous system disorders e.g. Alzheimer's disease,  
 CC infections caused by bacteria, viruses and fungi and ocular disorders  
 CC e.g. corneal infection. The polypeptides can also be used to aid wound

CC healing and epithelial cell proliferation, to prevent skin ageing due to  
 CC sunburn, to maintain organs before transplantation, for supporting cell  
 CC culture of primary tissues, to regenerate tissues and in chemotaxis. The  
 CC polypeptides can also be used as a food additive or preservative to  
 CC increase or decrease storage capabilities. Included in the invention are  
 CC polynucleotide sequences AAF64167 - AAF64175 and peptide AAB75505 which  
 CC are used in the isolation, identification and characterisation of the  
 CC proteins of the invention.

XX Sequence 167 AA:

Query Match 36.5%; Score 852; DB 22; Length 167;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-80;  
 Matches 167; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 287 LLYVTLAVCMENQIRIMAAKPKHDMTRSTFRAYMILLPSEFFYLSSVINPLTYV 346  
 Db 1 Llyvtlavcmnpqirimaakpkhdmtrstfraymllpseffylssvinpltylv 60  
 QY 347 SSGQFRFVVOYCCRLSLQHANHEKRLVHAHSTDSARFYORPLFPASRROSSARTE 406  
 Db 61 Ssgqfrfvtvqccrlslqhanekrlrvhahstdsarfyrpllpfssrrgsartte 120  
 QY 407 KIFLSTFQSEAEPOKSKQSLSESLSPNSGAKPANSAAENGFEHEV 453  
 Db 121 Kiflstfgseaeqsksgslsleslspnsgakpansaaengfgehev 167

RESULT 5

AAR98562 AAR98562 standard; Protein; 418 AA.

XX AC AAR98562;

DT 07-NOV-1996 (first entry)

XX DE Human neurotensin receptor.

XX KW neurotensin receptor; antagonist; agonist; screening; treatment; ulcer;  
 XX Parkinson's disease; depression; dementia; retrograde oesophagitis.

XX OS Homo sapiens.

XX PN JP08143597-A.

XX PD 04-JUN-1996.

XX PE 4-NOV-1994; 94JP-0289882.

XX PR 24-NOV-1994; 94JP-0289882.

XX PA (TAKE ) TAKEDA CHEM IND LTD.

XX DR WPI; 1996-318958/32.

XX DR N-PSDB; AAT33127.

XX PT DNA encoding human neurotensin receptor protein - useful for  
 XX screening for (ant)agonists used to treat, e.g. Parkinson's disease,  
 XX depression, dementia, retrograde oesophagitis, ulcers, etc.

XX PS Claim 1; Page 20-21; 26pp; Japanese.

XX CC The present sequence is that of a human neurotensin receptor protein  
 XX The DNA (AAT33127) encoding it and the protein are useful for screening  
 XX for (ant)agonists used to treat Parkinson's disease, depression,  
 XX dementia, retrograde oesophagitis, ulcers, etc..

XX SQ Sequence 418 AA:

Query Match 20.2%; Score 470.5; DB 17; Length 418;  
 Best Local Similarity 32.7%; Pred. No. 2.2e-40;

Matches 115; Conservative 66; Mismatches 136; Indels 35; Gaps 10;

QY 22 EFEVAT--WIKITLLVLIIFWGLGNSATIRVQVLOKRGY--LQKEVTDHMYSLAC 77  
 Db 53 eldvntldyskvlvtaylalfvgtvgn--tvtaflakkslqsgstvhlgslal 110  
 QY 78 SDILVFLIGMEFYSLIWNPLTSSYTLCKLHFLFECSTATLHLVTLSPERIAL 137  
 Db 111 sdilvlilampvelynflvwhpafgdagcrgyylfirdactyatalnvaslveryl 170  
 QY 138 CHPRKAVSGPCOVKLLIGFVWVTSALVALPLFLFAMGTEPLVNVSHRGILCNRSR 197  
 Db 171 chprkavlmsrtrkklfisaivlasallavpmlfmgteq-----nrsadg 216  
 QY 198 HHEDPETSNNMSICT--NLSSRWTFQSSIFGAPVYLVVLLVAFCMMVMQVLMK--S 252  
 Db 217 qh-----agvlvcvcpthlhtakvkvntlmstflfomvlsvIntliankltvmyrgaa 271  
 QY 253 QKSL--AGTRPPQLRKSESESR--ARROTIIFLLIYVTLAVCMNPDIRIMAAK 309  
 Db 272 eggvctvgsgh--stfamaieprvgalrhgyrvlavvialfvvcwlpvhrllmfcyl 329  
 QY 310 PKHDMTRSTFRAYMILLPSEFFYLSSVINPLTYVSSOOFRRFVQVLC 361  
 Db 330 sdegvtrpilyfyfnylymvvtallfvestlmpilylvnsanfnhfiatlac 381

RESULT 6

AAM66103 AAM66103 standard; Protein; 410 AA.

XX AC AAM66103;

DT 04-DEC-1998 (first entry)

XX DE Human type 2 neurotensin receptor protein.

XX KW Human; neurotensin type 2 receptor; hNT-R2; treatment; hormonal;  
 XX neurological disorder; neurotensin; thermo-regulation disorder; stress;  
 XX muscular contraction disorder; schizophrenia; analgesic; antipyretic.

XX OS Homo sapiens.

XX FH Key

XX FT Location/Qualifiers

XX FT 33..58 "transmembrane domain"

XX FT 71..91 "transmembrane domain"

XX FT 110..131 "transmembrane domain"

XX FT 155..175 "transmembrane domain"

XX FT 204..230 "transmembrane domain"

XX FT 297..315 "transmembrane domain"

XX FT 335..361 "transmembrane domain"

XX FT Domain

XX FR2760750-A1.

XX PD 18-SEP-1998.

XX PF 17-MAR-1997; 97FR-0003204.

XX PR 17-MAR-1997; 97FR-0003204.

XX PA (SNFI ) SANOFI SA.

XX PI Caput D, Chalon P, Ferrara P, Vita N;

XX DR WPI; 1998-508932/44.

XX DR N-PSDB; AAV07655.



Dd		311	lpyharlmcyvppddawtbdplnyfhywntltfyssavprllynawssffixkfl	370
Oy		357	QVLCRSLCHANE-KRLRVHASTT	382
Dd		371	eavs---slgehhpmkrllrpkpspt	394
RESULT		8		
AAR48724	ID	AAR48724 standard; Protein:	353 AA.	
AAR48724;	AC			
DT		06-JUN-1996 (first entry)		
DE		G-protein coupled rat neurotensin receptor protein.		
KW		"G-protein coupled receptor; ligand binding assay; transmembrane domain; psychotic disorder; schizophrenia; dopamine; CAMP; adenosine; thrombin; muscarinic acetylcholine; adrenergic; endothelin; bombesin; endocrine; rhodopsin; opsin; odorant; cytomagalovirus.  Rattus rattus.  WO9405695-AI.  17-MAR-1994.  09-SEP-1993; 93WO-US08528.  PE PR 10-SEP-1992; 92US-0943236.  XX (UYNK ) UNIV NEW YORK STATE.  PA Murphy RB, Schuster DI: PI PI PI WPI: 1994-101120/12.  DR XX Polypeptides of G-coupled receptor proteins (GPRs) - useful for PT binding GPR ligands or modulating GPR binding PT disclosure; Page 99-100; 160pp; English.  PS Proteins AAR48685-R48758 represent a range of G-protein coupled receptor XX proteins selected from cAMP, adenosine, muscarinic acetylcholine, CC adrenergic, thrombin, endothelin, bombesin, endocrine, rhodopsin, opsin, CC odorant, cytomegaloviral and other G-protein coupled receptors. The ● receptor proteins were used to design polypeptides, pref. based on the CC transmembrane domains, for use in G-protein coupled receptor ligand binding assays. The polypeptide fragments retain biological activity CC such as binding a GPR ligand or modulating GPR ligand binding to a GPR CC (see AAR48759-R48758, AAR50569-R50807 and AAR89189-R89195 for examples CC of polypeptide fragments). The polypeptide fragments can be used in CC compositions for treating subjects suffering from a pathology related to CC a GPR abnormality e.g. a psychotic disorder such as schizophrenia. CX XX Sequence      353 AA;		
SQ		Query Match	17.3%; Score 403.5; DB 15; Length 353;	
		Best Local Similarity	31.3%; Pred. No. 1,6e-33;	
		Matches 108; Conservative	59; Mismatches 133; Indels 45; Gaps 12;	
Oy		30	KITLILVLIIIFMGLNGSATIRYOVLOKKGY--LKEVTVDHWVSIALCSDIIVFLIGM	87
Dd		1	kvlveiyalvtvgtygnsvt--aftarkkslgstgvhyhsalsaldilllw--	56
Oy		88	PMEFYSIIW-NPLTSSSYTLCKLTFFELFACSYSATLLHVLTLSERTYATICHPPRYKAV	146
Dd		57	-velnyfiwhnpwadfdg-agcrgyyflindactyatalnvaslsveyralachpfikakcl	113
Oy		147	SQPQQVKLLIGVWWTSALVALPRLFAMQTEFRIVNVSPSHRDLTCNRSTRHHEDPETSN	206

```

Db      114 msrrtrtkkffisaivlaesallaipmflgtlq-----nrsdgth-----pg 154
QY      207 MSICTNLSRMT---VFQSSIFGAFVYLVVLLSVAFECMMQMYLM--KQKSLAGT 261
      111 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db      155 glvctprlvdtatvkvqlvntfmsflfpmlyvislntvianklcwmvqhgaegrvctvg 214
QY      262 RPPQLRKS----ESESSEST-ARRQTIIFLRILVYTLAVCAMPNQIRIRMAAKPKHDWTR 316
Db      215 thngelstfcmriepgavgrvqalrngvvlrtavvafvvcwlp-----ylcyisdgqrt 268
QY      317 SYFRAYMILLPESEFFEFLLSSVINPLTYVSSQOFRRVFOVLCC 361
      111 : : : : : : : : : : : : : : : : : : : : : :
Db      269 flfdtyhyfymlnalfvysaainpilynlvsanfrgyflstlac 313

RESULT      9
ID      AAM02696
AAW02696  AAW02696 standard; peptide; 353 AA.
XX
AC      AAW02696;
XX
DT      12-NOV-1996 (first entry)
XX
DE      G-protein coupled rat neurotensin receptor.
XX
KW      G-protein coupled receptor; ligand binding assay; transmembrane domain;
KW      schizophrenia; dopamine; cAMP; adenosine; thrombin; adrenergic; opsin;
KW      muscarinic acetylcholine; endothelin; bombesin; endocrine; rhodopsin;
KW      odorant; cytomagalovirus; serotoninergic.
XX
OS      Rattus rattus.
XX
PN      US5508384-A.
XX
PD      16-APR-1996.
XX
PF      10-SEP-1992; 92US-0943236.
XX
PR      09-SEP-1993; 93US-0118270.
XX
PR      10-SEP-1992; 92US-0943236.
XX
PA      (UYNV ) UNIV NEW YORK STATE.
PI      Murphy RB, Schuster DI:
XX
DR      WPI; 1996-208785/21.
XX
PT      New dopamine receptor peptide - useful as antipsychotic agent, e.g.
XX
PT      for treating schizophrenia
XX
PS      Disclosure: Column 117-120; 184pp; English.
XX
XX
XX      Proteins AAW02657-W02730 represent a range of G-protein coupled receptor
XX      (GPR) proteins selected from cAMP, adenosine, muscarinic acetylcholine,
XX      adrenergic, thrombin, endothelin, bombesin, endocrine, rhodopsin, opsin,
XX      odorant, cytomagaloviral and other GPR proteins. The receptor proteins
XX      were used to design polypeptides, pref. based on the transmembrane
XX      domains, for use in G-protein coupled receptor ligand binding assays.
XX      The polypeptide fragments retain biological activity such as binding a
XX      GPR ligand or modulating GPR ligand binding to a GPR (see
XX      AAW02747-W02999 for examples of polypeptide fragments). The polypeptide
XX      fragments can be used in compositions for treating subjects suffering
XX      from a pathology related to a GPR abnormality e.g. a psychotic disorder
XX      such as schizophrenia.
XX
Sequence 353 AA;
Query Match 17.3%; Score 403.5; DB 17; Length 353;
Best Local Similarity 31.3%; Pred. No. 1,6e-33;
Matches 108; Conservative 59; Mismatches 133; Indels 45; Gaps 12.

```

**CC** QY 30 KILIELVYLIIIFPMGLNSATIRTOYLOKKGY--LQKEVDHAWSLACSDIIVFLIGM 87  
**DB** :  
 Db 1 kvltaytialfivgvtgnsvt--aftarkksiqsgvctvhynssalsadlllilw-- 56  
**QY** 88 PMEFYSITW-NPLTTSSSYTLSCKLTHTPEACSVATLLHLVLTSFERYIAICHPFRYKAV 146  
 :  
**Db** 57 -vellyitwhpaefgd--agcrqyflirdactyatlnvaslverylatcphcfaktl 113  
**QY** 147 SGRCOVAKLIGFWWTASVALPLPFAMGCTEPLVNVPSSHNGLVCNSTRHHNQPTSN 206  
 :  
**Db** 114 msrircfkktisatlasallaipmftclqlq-----nrsqdth----pg 154  
**QY** 207 MSICTMLSSRMT---VFOSISFGAEFYLYLVYLLSVAFCMMVMOMVL--KSQSILAGT 261  
 :  
**Db** 155 glvcptivdcatkvxlgntfmstfilpmnlvislntvlankklvmvqhgaegrvctvg 214  
**QY** 262 RPPOLRKS-----ESESESR-ARRQTITIPLRIVTVLANCAMPNOIRRLMAAARKKHOTR 316  
 :  
**Db** 215 thnglehtfnmtlepgrvqalrhgvylrlravlaifvcwlp-----ylcylsdeqwrt 268  
**QY** 317 SYFRAYMIILPFESEFFELSVINPLELTVSSSQOFRRVEVOGCC 361  
 :  
**Db** 269 flidfyhyfymtenalfyvsaatnpillynvaafrqvfielae 313

**RESULT** 10 .  
**AA080598**  
**ID** AA080598 standard; Protein; 319 AA.  
**AC** AAM80598;  
**XX** XX  
**DT** 26-JAN-1999 (first entry)  
**XX** XX  
**DE** Human neurotensin receptor type 2.

KW Human; neurotensin receptor type 2; infection; bacterial; protozoan;  
 KW fungal; viral; HIV-1; HIV-2; cancer; anorexia; bulimia; asthma;  
 KW acute heart failure; Parkinson's disease; hypotension; hypertension;  
 KW urinary retention; osteoporosis; angina pectoris; myocardial infarction;  
 KW ulcer; allergy; benign prostatic hypertrophy; anxiety; schizophrenia;  
 KW psychotic; neurological disorder; manic depression; delirium; dementia;  
 KW severe mental retardation; dyskinesias; Huntington's disease;  
 KW Gilles de la Tourette's syndrome.

OS Homo sapiens.  
 XX OS  
 XX PN EP875568-A1.  
 XX PF 04-NOV-1998.  
 XX PP 01-APR-1998; 98EP-0302536.  
 XX PR 02-APR-1997; 97US-0832399.  
 XX RA (SMIK ) SMITHKLIN BEECHAM CORP.  
 XX PL Bergsma DJ, Shabon U;  
 XX WPI; 1998-559434/48.  
 XX DR N-PADB; AAV62449.  
 CC PT New human neurotensin receptor type 2 polypeptide and polynucleotide  
 CC PT - useful as diagnostic reagents and for treating e.g. HIV infection,  
 CC PT cancer and osteoporosis  
 XX PT  
 PS Claim 11; Page 7-8; 26pp; English.

The present sequence represents human neurotensin receptor type 2 (hNR). hNR polypeptides and polynucleotides are useful for diagnosing diseases related to over or underexpression of hNR protein by identifying mutations in the hnr gene using hnr probes, or determining hnr protein or mRNA expression levels. hnr polypeptides are also useful for screening compounds which affect activity of the protein. These compounds can

CC be used for treatment to inhibit (antagonist) or enhance (agonist) hNR  
CC activity, in addition to direct administration of hNR polypeptides to  
CC treat conditions associated with a lack of hNR protein or direct  
CC administration of antisense sequences to prevent expression. Gene therapy  
CC may also be used to affect endogenous hNR polypeptide production. Vaccines  
CC comprising hNR polypeptides can be used for inoculation against diseases,  
CC and antibodies are useful for inducing an immune response to prevent and  
CC treat disease, and isolating clones or purifying polypeptides by affinity  
CC chromatography. Diseases prevented, diagnosed and treated include: HIV-1  
CC or HIV-2 infections; pain; cancers; anorexia; bulimia; asthma; acute  
CC heart failure; Parkinson's disease; hypotension; hypertension; urinary  
CC retention; osteoporosis; angina pectoris; myocardial infarction; ulcers;  
CC allergies; benign prostatic hypertrophy; and psychotic and neurological  
CC disorders, including anxiety, schizophrenia, manic depression, delirium,  
CC dementia, severe mental retardation and dyskinesias, such as Huntington's  
CC disease or Gilles de la Tourette's syndrome. The hNR polypeptides are  
CC also useful for mapping the gene to a chromosome, allowing gene  
CC inheritance to be studied through linkage analysis.

Query Match	15.9%;	Score 370.5;	DB 19;	Length 319;
Best Local Similarity	26.1%;	Pred. No. 3.9e-30;		
Matches	93;	Conservative	57;	Mismatches 123; Indels 83; Gaps 7,

```

Oy      28 WIKTLLILVYLIVFMGLGSSAIRVOWLOKKGUYLOKEVTHDMSASDILVFLGM      8
Db      30 wakvlfafalyalivalgaagnalsvhw--vlkaragragrtrhhvlsalalaglllllvgy      87
Oy      88 PMERYSTIIMNPLTSSSTYLLSCKMLTFLEFGCSVTLLHVLTSERYIALCHPRRYKAS      147
Db      88 pvelstfwmfhyppwfrldlgrgyrfvnelcalayatsvagaIserecIacqcpItrastll      147
Oy      148 GPCCVKLLIGFVWVTSALVALPRLPFAMGTEPYLAVNVPSNRGLTGNRSSTRNHNEOPTSNM      207
Db      148 tprtrftrivalsaaalsglalpmavimgqkheletad-----erepas-      191
Oy      208 SICNTLSRMRWVFOGSIIGCAVYVYLVLVLSAFAFMCMNMGOYVLMKSQKSLAGARRPQLR      265
Db      192 tvclvlyast-----talgyflq-----      207
Oy      268 KSESEESTARQTIIFLRLIVTLAVCMENQIRIRIAAKAPKNDWTRSYRAYMILLP      322
Db      209 -----ealivmlylclwlyharitlmcyvvpddawcdpIynfhyfym      250
Oy      328 FSEPFYLLSVINPLLYTVSSGSPRRVVOVLCRSLQIHNHNE-KRLRVHAHSTT      382
Db      251 vlnlflvysavtrpIlynaavssffiklleavss--slcgeghpmktrIprkppqgpt      303

```

RESULT	11
AA663367	
ID	AA663367 standard; Protein; 395 AA.
XX	
XX	
AC	AA663367;
XX	
DF	15-OCT-2001 (first entry)
XX	
DE	Amino acid sequence of a rat TGR-1 protein.
XX	
KW	TGR-1; neuromedin U; hypertension; stress disease
XX	
OS	Rattus sp.
XX	
PN	W0200157524-A1.
XX	
PD	09-AUG-2001.
XX	
PF	02-FEB-2001; 2001MO-JP00746.
XX	
PR	04-FEB-2000; 2000JP-0032773.
XX	
PR	24-FEB-2000; 2000JP-0052252.







Db 244 vevkgktaatqetshrrtqldq--rgrtqvtkmlfalvvyfgicwapfhadrimsly 301

QY 311 KHDWTSYFRAYMILLPSEFFYLSVINPLLYTVSSQOFRRFVQVL-----CC-RLS 364

Db 302 ghs-teglhlayqcvhiasgiffylygsaanpvlyslmsrtfretflqalqygtqchrrq 360

QY 365 LOHANHEKRLRVHAHSTTDS 384

Db 361 pyhgshn-----hirltgs 375

RESULT 13

AAB9186 standard; Protein; 405 AA.

AC AAB9186;

XX

DT 03-SEP-2001 (first entry)

XX

DE Murine FM-3.

XX

KM Murine; FM-3; hypotensive; tranquiliser; neuromedin U; stress;

KW hypertension; appetite regulator.

XX

OS Mus musculus.

XX

PN WO200140797-A1.

PD 07-JUN-2001.

XX

PF 28-NOV-2000; 2000MO-JP08363.

XX

PR 29-NOV-1999; 99JP-0338387.

PR 24-FEB-2000; 2000JP-0052251.

XX

PA (TAKE ) TAKEDA CHEM IND LTD.

XX

PI Hinuma S, Hosoya M, Kawamata Y, Fukusumi S;

XX

DR WPI; 2001-374952/39.

DR N-PSDB; AAAH5073.

XX

PT Method for screening for compounds that alter binding between

PT neuromedin U and FM-3 useful for treatment of stress, hypertension and

PT for regulating appetite

XX

PS Disclosure; Page 78-79; 92pp; Japanese.

XX

CC The present invention relates to a method for screening for compounds

CC that alter binding between neuromedin U and its derivatives to FM-3 and

CC its salts. The present sequence is the protein sequence for murine FM-3,

CC which was used in the method of the present invention. The compounds

CC found using the method of the present invention are useful for the

CC treatment and prevention of stress, hypertension and also as an appetite

CC regulator.

XX

SQ Sequence 405 AA;

Query Match 15.6%; Score 363; DB 22; Length 405;

Best Local Similarity 29.2%; Pred. No. 3,3e-29;

Matches 111; Conservative 55; Mismatches 146; Indels 68; Gaps 15;

QY 31 ITLLIVIIIFVWGLNSATIRVTOVLQKKGYLOKEVTDHMSLACSDILVILGKPM 90

Db 38 vpicvtyllifvvgfllgylt--ctvllrnk-tmrtptnflfslavsdmlvlvgjp 94

QY 91 FYSTIWM-PLTTSVTISCKRHTFLFECASYATLHVLTLSFEYIACHPFRYKAVSGP 149

Db 95 Iymeqnypfqlga--sacyfrllllevciasvlnvtalveyvavvprlqeksvmtr 152

QY 150 COVKLLIGFVWTSALVALPLLFAMGTEYPLVNVPSHRGLTGNRSSTRHHQDPTSNMSI 209

Db 153 ahvrrmgaiwlatlalfpntslhglsg--ltvpc-rg-----pvdasai 195

QY 210 CTNLSSKRTVVOSSIFGAFVYLVVLLSVA--FKCGNNMOV-----IM 250

Db 196 c-----slvgsmdfykvlvltaltallfclpmtvtsvlylllgllrrermllq 243

QY 251 KSGKSLAGTRPPQLRKSESESESRARQRTIFRLVLTVLAVCMNPQIRIRIMAAPK 310

Db 244 vevkgktaatqetshrrtqldq--rgrtqvtkmlfalvvyfgicwapfhadrimsly 301

QY 311 KHDWTSYFRAYMILLPSEFFYLSVINPLLYTVSSQOFRRFVQVL-----CC-RLS 364

Db 302 ghs-teglhlayqcvhiasgiffylygsaanpvlyslmsrtfretflqalqygtqchrrq 360

QY 365 LOHANHEKRLRVHAHSTTDS 384

Db 361 pyhgshn-----hirltgs 375

RESULT 14

AAB67803 standard; Protein; 412 AA.

AC AAB67803;

XX

DT 29-JUN-2001 (first entry)

XX

DE Amino acid sequence of G-protein coupled receptor IGS4A short version.

XX

KW Human; G-protein coupled receptor; IGS4; IGS4A; IGS4B; schizophrenia;

KW nervous system disorder; psychiatric disorder; Parkinson's disease;

KW episodic paroxysmal anxiety; phobia; migraine; epilepsy; bulimia; stroke;

KW cardiovascular disease; heart failure; angina pectoris; obesity; emesis;

KW motility disorder; myocardial infarction; hypertension; dyslipidemia;

KW gastrointestinal disorder; inflammatory bowel disease; osteoporosis;

KW inflammation; infection; pain; cancer; immune disorder; allergy; sepsis;

KW gynecological disorder.

XX

OS Homo sapiens.

XX

PN WO200125269-A2.

PD 12-APR-2001.

XX

PF 25-SEP-2000; 2000MO-BP09584.

XX

PR 24-SEP-1999; 99EP-0203140.

PR 24-SEP-1999; 99NL-1013140.

PR 28-JUL-2000; 2000EP-0202683.

PR 31-JUL-2000; 2000US-0222047.

XX

PA (SOLV ) SOLVAY PHARM BV.

XX

PI Deleersnijder W, Berger C, Loeken C, Nys G, Venema J;

XX

DR WPI; 2001-273568/28.

DR N-PSDB; AAF80323.

XX

PT New G-protein coupled receptors and the polynucleotides encoding them,

PT useful for preventing, ameliorating or correcting nervous system

PT disorders, cardiovascular diseases, dyslipidemias, inflammations, pain

PT or cancers

XX

PS Claim 18; Page 81-82; 102pp; English.

XX

CC The present sequence represents the short version of a human G-protein

CC coupled receptor designated IGS4A. IGS4 exists in two polymorphic forms,

CC IGS4A and IGS4B. The IGS4 receptors and IGS4 polynucleotides are useful

CC for preventing, ameliorating or correcting dysfunction or diseases.

CC These diseases include peripheral nervous system, psychiatric and central

CC nervous system disorders (e.g. schizophrenia, episodic paroxysmal

CC anxiety, phobia, Parkinson's disease, migraine, epilepsy, bulimia or

CC stroke), cardiovascular diseases (e.g. heart failure, angina pectoris,



Wed Jan 9 08:51:39 2002

us-09-635-521a-2.rag

Page 11

Search completed: January 8, 2002, 23:03:24  
Job time: 2374 sec

---

